XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.1
1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Noncontrolling interests $ (132,124) $ (126,031)
Cash equivalents 0 0
Cash balances over insured amount 9,415,000  
Asset impairment charges $ 0 $ 0
Shares considered antidilutive 2,072,492 437,784
Amortization of deferred financing costs $ 0 $ 0
Contract revenue 650,187 229,625
Research and development expenses 927,000 896,000
National Institute of Health [Member]    
Contract revenue 650,187 229,625
National Institute of Health [Member] | Melanoma Cancer Contract Phase 2 [Member]    
Contract revenue 620,187  
National Institute of Health [Member] | Melanoma Cancer Contract Phase 1 [Member]    
Contract revenue   149,625
National Institute of Health [Member] | Breast Cancer Grant [Member]    
Contract revenue 30,000 $ 80,000
Deferred revenue $ 100,000  
ESI [Member]    
Equity ownership percentage 80.00% 80.00%
Noncontrolling interests $ (132,124) $ (126,031)